H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Additional blockbuster drugs may be on the horizon.

H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch

H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch

SpaceX Joins Nasdaq 100; Crinetics Pharmaceuticals Soars on Buyout | Stock Movers

On this episode of Stock Movers: - Fiserv (FISV) is climbing as the Wall Street Journal reports big banks including JPMorgan Chase, Bank of America, Wells Fargo and PNC Financial Services Group have held preliminary discussions about a deal to acquire a network owned by the financial-technology company Fiserv. - Crinetics Pharmaceuticals (CRNC) is soaring after Vertex Pharmaceuticals agreed to buy Crinetics for 10 billion in cash to expand into endocrinology. - SpaceX (SPCX) is lower even though at least six brokers, including Morgan Stanley and Goldman Sachs, have started coverage of SpaceX with buy-equivalent ratings. SpaceX’s addition to the Nasdaq 100 should provide considerable support to the stock, considering the number of funds that track the tech-heavy benchmark. (Source: Bloomberg)

Contributor: Mental health care isn't ready for psychedelic side effects

Accelerated FDA approval will invite recklessness. But don't block these important medications. Take steps to prepare.

Sensex today | Stock Market Live: Stock to buy today: Piramal Pharma 

Sensex, Nifty, Share Prices LIVE: The stock of Piramal Pharma has been in an uptrend after it found support at 132 in March. While there was some correction in May and June, the broader picture remains positive. The chart shows that the stock has formed a higher low at 158 compared to the support at 132.

Ascendis Pharma: Behind The Stock Surge

Ascendis Pharma: Behind The Stock Surge

FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports

Documents reviewing the research on peptides note lack of good evidence of efficacy or safety. Yet an FDA panel will consider easing access to them later this month.

Supreme Court rules federal law shields Monsanto from Roundup cancer lawsuits

The 7-2 ruling found that EPA's approval of Roundup's label without a cancer warning preempts state failure-to-warn claims

Cancer Patients Swapping Chemotherapy for Ivermectin as Oncologists Sound Alarm

A JAMA Network Open study tracking 68 million patient records found ivermectin prescriptions among cancer patients more than doubled after Mel Gibson's Joe Rogan interview. The American Society of Clinical Oncology says there is no clinical evidence the antiparasitic drug treats cancer and that its interactions with chemotherapy remain incompletely understood.

The billion-dollar rig: How Pharma’s grip on government turns medicine into a pay-to-play system

(NaturalNews) Pharmaceutical companies now fund nearly 51 of the FDA's budget through user fees, creating a financial conflict of interest in drug regulation. ...

Could Polymarket’s $6.5mln lawsuit reshape prediction-market disputes?

If correct predictions can lose, what exactly are traders buying?

Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.

A New Vaccine Option Is Now Available for Kids with Diabetes, Heart Disease, or Other Chronic Conditions

FDA approved Capvaxive for kids 2-17 with chronic conditions like diabetes and heart disease, June 18, 2026. Here's what families managing pediatric chronic illness need to know.

Supreme Court Hands Monsanto a Major Shield Against Roundup Cancer-warning Lawsuits

The Supreme Court has handed Monsanto a corporate liability victory this term, saying Roundup does not need a cancer warning label. ... The post Supreme Court Hands Monsanto a Major Shield Against Roundup Cancer-warning Lawsuits appeared first on The New American.